Clone of Alzheimer's - Prevention Beyond the Pipeline

Eligibility

Funding is open to researchers, clinicians, and postdoctoral fellows in the U.S. and worldwide working in:

  • Academic medical centers and universities or nonprofits. Industry partnerships are strongly encouraged.
  • Biotechnology companies. Funding is provided through mission-related investments that require return on investment based upon scientific and/or business milestones. Existing companies and new startups are both eligible.
  • The ADDF seeks to support comparative effectiveness research, prevention clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline.

  • FUNDING PRIORITIES

    Consortium of Cohorts for Alzheimer's Prevention Action (CAPA): Epidemiological studies contribute unmatched information on whether the risk of dementia or cognitive decline may be influenced by long-term exposure to specific foods or supplements. However, high-powered studies are needed, ideally with dose, duration, and responder profiles, in order to translate epidemiological research into actionable interventions for testing. Through the CAPA Consortium, the ADDF funds collaborative analyses on dementia prevention using a minimum of five longitudinal cohorts, either harmonized or analyzed through parallel analysis of cohorts using a shared analysis script. More information here. More information here.

    Comparative Effectiveness Research: For many health conditions, physicians have a choice of clinically equivalent drugs. Some of these drugs are being investigated for repurposing to treat Alzheimer's or related dementias, due to potential disease-modifying properties that go beyond the treatment of their approved disease indication. The ADDF will consider funding research to generate an evidence base on whether choices in the routine clinical care of pre-existing conditions could protect from dementia. Priority will be given to the comparison of drugs that are otherwise clinically equivalent for the pre-existing condition (see Box 1 in the ADDF 2016 position paper). Methods may include randomized trials or epidemiology.

    Cognitive Decline and Cognitive Reserve: Cognitive decline through aging and health conditions has been linked to an increased risk of dementia. The ADDF will consider funding programs to prevent and treat these conditions, including cognitive aging, menopause-related cognitive symptoms, postoperative delirium and postoperative cognitive decline, mild and/or repetitive traumatic brain injury, and chemotherapy-induced decline. Methods may include clinical trials or epidemiology.

UPCOMING DEADLINES

Must be received by 5:00 pm ET on the deadline date.

Letter of Intent
January 18, 2019

Invited Full Proposal
February 8, 2019

Letter of Intent
April 12, 2019

Invited Full Proposal
May 10, 2019

Letter of Intent
July 12, 2019

Invited Full Proposal
August 9, 2019

Letter of Intent
October 11, 2019

Invited Full Proposal
November 8, 2019

The ADDF considers its application process an iterative one, and we would be happy to talk to you about your program. 

For program-related inquiries, please contact:
Yuko Hara, PhD, Director, Aging & Alzheimer's Prevention
yhara@alzdiscovery.org

For application submission inquiries, please contact:
Grants and Mission-Related Investments Team
grants@alzdiscovery.org

Agency Name: 
Alzheimer's Drug Discovery Foundation -
Contact Name: 
Penny D'Agnone
Grant Amount: 
Average Duration - One year for epidemiological analyses - Varies (multi-year) for clinical trials Average Award - $50,000-$100,000 for epidemiological analyses based on scope of research - Up to $3 million for clinical trials based on stage and scope of research. For studies requiring additional support, co-funding from other funding agencies or investors is encouraged.
Grant Location: 
External
External Deadline: 
Friday, April 12, 2019
Grant Type: 
Research
Grant Area: 
Health
Grant Eligibility: 
Faculty